Trial Profile
The comparative study of efficacy and safety in the treatment with mixed-type insulin to combined therapy with long-acting insulin analog and GLP-1 recepter agonist in type 2 DM.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary) ; Insulin; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 27 Feb 2017 Status changed from active, no longer recruiting to completed.
- 05 Mar 2015 New trial record